China’s National Medical Products Administration approves imports of Johnson & Johnson’s (NYSE:JNJ) Tremfya.
Tremfya will be used to treat moderate to severe plaque psoriasis in adults who aren’t candidates for systemic therapy.
https://seekingalpha.com/news/3528535-johnson-johnsons-tremfya-gets-china-approval
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.